02 February 2015 : Original article
Differential Impact of Risk Factors for Tumor Recurrence in Hepatitis B and Hepatitis C Virus-Infected Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma
Maciej KrasnodębskiABCDEF, Michał GrątACD, Łukasz MasiorBEF, Waldemar PatkowskiAD, Marek KrawczykADDOI: 10.12659/AOT.892395
Ann Transplant 2015; 20:70-75
Abstract
BACKGROUND: Hepatitis B (HBV) and C (HCV) virus infection are the 2 most important risk factors for the development of the hepatocellular carcinoma (HCC). The aim of this study was to assess the importance of the type of viral infection in evaluation of HCC recurrence risk after liver transplantation (LT).
MATERIAL AND METHODS: This retrospective study was based on 130 HCC patients undergoing LT. Patients were subdivided by HBV or HCV infection only or HBV and HCV co-infection (HBV-HCV). The primary outcome measure was recurrence-free survival (RFS) 5 years after transplantation.
RESULTS: The 5-year RFS did not differ significantly according to HBV infection, HCV infection, or HBV-HCV co-infection in the entire study cohort (p=0.902) or among patients who fulfilled (p=0.454) or did not fulfill (p=0.999) the Milan criteria. Neither HCV (p=0.869) nor HBV (p=0.968) infection significantly affected 5-year RFS following adjustment for covariates. Higher lesion number (p=0.004), increased alpha-fetoprotein (p=0.017), microvascular invasion (p=0.004), and female donor sex (p=0.025) were significant risk factors for poor RFS in HBV patients; older recipient age (p=0.010) and increased total tumor volume (p=0.028) were significant risk factors in HCV patients.
CONCLUSIONS: Although the viral infection type does not affect post-LT outcomes in HCC patients, the influence of other risk factors is markedly different in HBV- and HCV-related HCC.
Keywords: alpha-Fetoproteins, Hepatitis B virus, Hepatitis C Antibodies, Liver Transplantation, Patient Outcome Assessment
In Press
Original article
Fundamental Strategies and Technical Perspectives in Bile Duct Anastomosis for Living Donor Liver Transplan...Ann Transplant In Press; DOI: 10.12659/AOT.953761
Clinical Research
Retrospective Study of Implementation and Outcomes of a Non-Cryopreserved Autologous Hematopoietic Stem Cel...Ann Transplant In Press; DOI: 10.12659/AOT.954230
Clinical Research
Prognostic Prediction in Living Donor Liver Transplantation Recipients With Complete Pathological Response ...Ann Transplant In Press; DOI: 10.12659/AOT.954574
Most Viewed Current Articles
24 Aug 2021 : Review article 21,978
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original article 18,247
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
22 Nov 2022 : Original article 16,856
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
05 Apr 2022 : Original article 16,762
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604






